There are currently 45 clinical trials in Round Rock, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including Central Texas Neurology Consultants, Novo Nordisk Investigational Site, Texas Oncology-Seton Williamson and Texas Oncology - Round Rock Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT06190093
Recruiting
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
Gender:
All
Ages:
50 years and above
Trial Updated:
04/26/2024
Locations: Clinical Site, Round Rock, Texas
Conditions: Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
Register for Updates
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
NCT06268886
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/26/2024
Locations: Central Texas Neurology Consultants (CTNC), Round Rock, Texas +1 locations
Conditions: Alzheimer Disease, Early Onset
Register for Updates
AMX0035 and Progressive Supranuclear Palsy
NCT06122662
Recruiting
ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo controlled phase, followed by an optional open-label extension phase.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
04/25/2024
Locations: Central Texas Neurology Consultants, Round Rock, Texas
Conditions: Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Register for Updates
Long-Term Follow-Up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
NCT05232929
Recruiting
A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study,... Read More
Gender:
All
Ages:
All
Trial Updated:
04/25/2024
Locations: Central Texas Neurology Consultants, Round Rock, Texas
Conditions: Spinal Muscular Atrophy
Register for Updates
Early Parkinson's Disease Monotherapy With CVN424
NCT06006247
Recruiting
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not t... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
04/24/2024
Locations: Central Texas Neurology Consultants, Round Rock, Texas
Conditions: Parkinson's Disease
Register for Updates
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
NCT04899336
Recruiting
The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia coli disease (IED) event caused by ExPEC9V O-serotypes.
Gender:
All
Ages:
60 years and above
Trial Updated:
04/23/2024
Locations: Be Well Clinical Studies, Round Rock, Texas
Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Register for Updates
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
NCT05669755
Recruiting
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected br... Read More
Gender:
All
Ages:
55 years and above
Trial Updated:
04/19/2024
Locations: Texas Diabetes & Endocrinology_Round Rock, Round Rock, Texas
Conditions: Cardiovascular Disease
Register for Updates
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
NCT06055985
Recruiting
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
04/18/2024
Locations: Pd0060 50496, Round Rock, Texas
Conditions: Parkinson Disease
Register for Updates
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Scott & White Hospital - Round Rock, Round Rock, Texas
Conditions: Breast Neoplasms
Register for Updates
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
NCT05348785
Recruiting
In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study: Participants will take 225 milligrams (mg) of BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but has no real medicine in it. Participants will take BIIB122 or placebo 1 time a day for up to a minimum of 48 weeks and a maximum of 144 weeks. Certain medications for PD will be allowed at enrollment for a subset of part... Read More
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
04/17/2024
Locations: Central Texas Neurology Consultants, Round Rock, Texas
Conditions: Parkinson Disease
Register for Updates
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114
Recruiting
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/17/2024
Locations: Novartis Investigative Site, Round Rock, Texas
Conditions: Relapsing Multiple Sclerosis
Register for Updates
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709
Recruiting
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤60%.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Baylor Scott and White Research Institute - Round Rock, Round Rock, Texas
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Register for Updates